Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.

Bottorff MB, Bright DR, Kisor DF.

Pharmacotherapy. 2017 Sep;37(9):1005-1013. doi: 10.1002/phar.1979. Epub 2017 Aug 15. Review.

PMID:
28654154
2.

The relationship between four health-related quality-of-life indicators and use of mammography and Pap test screening in US women.

Gandhi PK, Gentry WM, Kibert JL 2nd, Lee EY, Jordan W, Bottorff MB, Huang IC.

Qual Life Res. 2015 Sep;24(9):2113-28. doi: 10.1007/s11136-015-0968-9. Epub 2015 Mar 25.

3.

Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.

Gandhi PK, Gentry WM, Ma Q, Bottorff MB.

J Manag Care Spec Pharm. 2015 Feb;21(2):165-75.

4.

Alternative viewpoint: preparation for residency.

Knapp KK, Mészáros K, Goldsmith PC, McCarter GC, Hester EK, McBane SE, Bottorff MB, Carnes TA, Dell K, Gonyeau MJ, Greco AJ, McConnell KJ, Skaar DJ, Splinter MY, Trujillo TC.

Pharmacotherapy. 2014 Aug;34(8):e157-8. doi: 10.1002/phar.1475. No abstract available.

PMID:
25112527
5.

Educational outcomes necessary to enter pharmacy residency training.

Hester EK, McBane SE, Bottorff MB, Carnes TA, Dell K, Gonyeau MJ, Greco AJ, McConnell KJ, Skaar DJ, Splinter MY, Trujillo TC.

Pharmacotherapy. 2014;34(4):e22-5. doi: 10.1002/phar.1411.

PMID:
24753155
6.

Investigation of pegloticase-associated adverse events from a nationwide reporting system database.

Gentry WM, Dotson MP, Williams BS, Hartley M, Stafford KR, Bottorff MB, Gandhi PK.

Am J Health Syst Pharm. 2014 May 1;71(9):722-7. doi: 10.2146/ajhp130571.

PMID:
24733135
7.

Dabigatran-dronedarone interaction in a spontaneous reporting system.

Gandhi PK, Gentry WM, Bottorff MB.

J Am Pharm Assoc (2003). 2013 Jul-Aug;53(4):414-9. doi: 10.1331/JAPhA.2013.12218.

PMID:
23892815
8.

Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.

Gandhi PK, Gentry WM, Bottorff MB.

Semin Arthritis Rheum. 2013 Jun;42(6):562-6. doi: 10.1016/j.semarthrit.2012.11.002. Epub 2013 Jan 24.

PMID:
23352248
11.

Statin safety and drug interactions: clinical implications.

Bottorff MB.

Am J Cardiol. 2006 Apr 17;97(8A):27C-31C. Epub 2006 Jan 25. Review.

PMID:
16581325
12.

Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacy.

Toscani MR, Makkar R, Bottorff MB.

J Manag Care Pharm. 2004 Nov;10(6 Suppl A):S2-12; quiz S13-6. Review.

PMID:
15546222
13.

Statin safety: what to know.

Bottorff MB.

Am J Geriatr Cardiol. 2004 May-Jun;13(3 Suppl 1):34-8. Review. No abstract available.

PMID:
15133428
14.

New roles for antiplatelet agents in treatment of atherothrombotic diseases.

Bottorff MB.

J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2 Suppl 1):S4. No abstract available.

PMID:
15095930
15.

Underidentification and undertreatment issues.

Bottorff MB.

J Manag Care Pharm. 2003 Jan-Feb;9(1 Suppl):6-8.

16.

Combination antiplatelet therapy: implications for pharmacists.

Talbert RL, Spinier SA, Nappi JM, Bottorff MB.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):880-3.

PMID:
12482014
17.

Combination antiplatelet therapy: implications for pharmacists.

Talbert RL, Spinler SA, Nappi JM, Bottorff MB.

Pharmacotherapy. 2002 Oct;22(10):1211-5. Review.

PMID:
12389871
18.

Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.

Bottorff MB, Tenero DM.

Pharmacotherapy. 1999 Apr;19(4 Pt 2):73S-78S. Review.

PMID:
10213525
19.
20.

Aging effects on the organic base transporter and stereoselective renal clearance.

Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML.

Clin Pharmacol Ther. 1997 Aug;62(2):117-28.

PMID:
9284847
21.

Hypertonic saline does not reverse the sodium channel blocking actions of lidocaine: evidence from electrophysiologic and defibrillation studies.

Ujhelyi MR, Schur M, Frede T, Bottorff MB, Gabel M, Markel ML.

J Cardiovasc Pharmacol. 1997 Jan;29(1):61-8.

PMID:
9007672
22.

Influence of hypertonic saline solution infusion on defibrillation efficacy.

Ujhelyi MR, Winecoff AP, Schur M, Frede T, Bottorff MB, Gabel M, Markel ML.

Chest. 1996 Sep;110(3):784-90.

PMID:
8797427
23.

Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance.

Ujhelyi MR, Schur M, Frede T, Bottorff MB, Gabel M, Markel ML.

J Am Coll Cardiol. 1996 May;27(6):1534-42.

24.

Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner.

Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML.

J Pharmacol Exp Ther. 1996 Feb;276(2):683-9.

PMID:
8632337
25.

Heart failure: evaluation and care of patients with left ventricular systolic dysfunction.

Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, et al.

J Card Fail. 1995 Mar;1(2):183-7. No abstract available.

PMID:
9420649
26.

Therapeutic options in the treatment of congestive heart failure. Part II.

Bottorff MB.

Director. 1994 Winter;2(1):15-7. No abstract available.

PMID:
7859120
27.

Therapeutic options in the treatment of congestive heart failure. Part I.

Bottorff MB.

Director. 1993 Oct;1(1):34-6. No abstract available.

PMID:
7850522
28.

Advances in antiarrhythmic drug therapy.

Harrison DC, Bottorff MB.

Adv Pharmacol. 1992;23:179-225. Review. No abstract available.

PMID:
1540535
29.

Pharmacokinetic interactions with calcium channel antagonists (Part II).

Schlanz KD, Myre SA, Bottorff MB.

Clin Pharmacokinet. 1991 Dec;21(6):448-60. Review.

PMID:
1782739
30.

Pharmacokinetic interactions with calcium channel antagonists (Part I).

Schlanz KD, Myre SA, Bottorff MB.

Clin Pharmacokinet. 1991 Nov;21(5):344-56. Review.

PMID:
1773549
31.

Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition.

Lalonde RL, O'Rear TL, Wainer IW, Drda KD, Herring VL, Bottorff MB.

Clin Pharmacol Ther. 1990 Nov;48(5):509-19.

PMID:
2225711
32.

Altered beta-adrenergic sensitivity and protein binding to 1-propranolol in the elderly.

Tenero DM, Bottorff MB, Burlew BS, Williams JB, Lalonde RL.

J Cardiovasc Pharmacol. 1990 Nov;16(5):702-7.

PMID:
1703590
33.

Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers.

Hunt BA, Bottorff MB, Herring VL, Self TH, Lalonde RL.

Clin Pharmacol Ther. 1990 May;47(5):584-91.

PMID:
2344707
34.

Effects of age on the protein binding and disposition of propranolol stereoisomers.

Lalonde RL, Tenero DM, Burlew BS, Herring VL, Bottorff MB.

Clin Pharmacol Ther. 1990 Apr;47(4):447-55.

PMID:
2328552
35.

Pharmacokinetics and pharmacodynamics of dilevalol.

Tenero DM, Bottorff MB, Given BD, Kramer WG, Affrime MB, Patrick JE, Lalonde RL.

Clin Pharmacol Ther. 1989 Dec;46(6):648-56.

PMID:
2598569
36.

The effect of diltiazem on the disposition of encainide and its active metabolites.

Kazierad DJ, Lalonde RL, Hoon TJ, Mirvis DM, Bottorff MB.

Clin Pharmacol Ther. 1989 Dec;46(6):668-73.

PMID:
2513160
37.

Calcium channel blockers as inhibitors of drug metabolism.

Hunt BA, Self TH, Lalonde RL, Bottorff MB.

Chest. 1989 Aug;96(2):393-9. Review. No abstract available.

PMID:
2568899
38.

The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine.

Bottorff MB, Lalonde RL, Kazierad DJ, Hoon TJ, Tsiu SJ, Mirvis DM.

Pharmacotherapy. 1989;9(5):315-21.

PMID:
2510135
40.

Nonlinear accumulation of propranolol enantiomers.

Lalonde RL, Bottorff MB, Straka RJ, Tenero DM, Pieper JA, Wainer IW.

Br J Clin Pharmacol. 1988 Jul;26(1):100-2.

41.

Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension.

Bottorff MB, Hoon TJ, Rodman JH, Gerlach PA, Ramanathan KB.

J Clin Pharmacol. 1988 May;28(5):420-6.

PMID:
3392239
42.

The relative predictive performance of two theophylline pharmacokinetic dosing programs.

Hoon TJ, Wood CA Jr, Whidden MA, Greene WL, Bottorff MB.

Pharmacotherapy. 1988;8(2):82-8.

PMID:
3399424
43.

Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.

Lalonde RL, Straka RJ, Pieper JA, Bottorff MB, Mirvis DM.

J Pharmacokinet Biopharm. 1987 Dec;15(6):569-82.

PMID:
3450842
44.

Liquid chromatography and fluorescence polarization immunoassay methods compared for measuring flecainide acetate in serum.

Straka RJ, Hoon TJ, Lalonde RL, Pieper JA, Bottorff MB.

Clin Chem. 1987 Oct;33(10):1898-900.

45.

Nonlinear pharmacokinetics of unbound propranolol after oral administration.

Straka RJ, Lalonde RL, Pieper JA, Bottorff MB, Mirvis DM.

J Pharm Sci. 1987 Jul;76(7):521-4.

PMID:
3668812
46.

Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.

Bottorff MB, Lalonde RL, Straughn AB.

Biopharm Drug Dispos. 1987 May-Jun;8(3):213-21.

PMID:
3297181
47.

Interference with digoxin immunoassays.

Bottorff MB, Phelps SJ, Hoon TJ.

Clin Pharm. 1987 Feb;6(2):100-2. No abstract available.

PMID:
3665365
48.

Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.

Lalonde RL, Pieper JA, Straka RJ, Bottorff MB, Mirvis DM.

Eur J Clin Pharmacol. 1987;33(3):315-8.

PMID:
3691620
49.

Lidocaine protein binding in preeclampsia.

Bottorff MB, Pieper JA, Boucher BA, Hoon TJ, Ramanathan J, Sibai BM.

Eur J Clin Pharmacol. 1987;31(6):719-22.

PMID:
3556378
50.

Effect of age and serum creatinine on endogenous digoxin-like substances in infants and children.

Phelps SJ, Kamper CA, Bottorff MB, Alpert BS.

J Pediatr. 1987 Jan;110(1):136-9.

PMID:
3540246

Supplemental Content

Loading ...
Support Center